NCT07678320

Brief Summary

Single-center, cross-sectional observational study assessing the feasibility of advanced accelerated MRI sequences versus standard ones in terms of image quality, diagnostic reliability, and acquisition time.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
600

participants targeted

Target at P75+ for all trials

Timeline
34mo left

Started Jul 2026

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress3%
Jul 2026May 2029

First Submitted

Initial submission to the registry

June 25, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 1, 2026

Completed
Same day until next milestone

Study Start

First participant enrolled

July 1, 2026

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2028

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2029

Last Updated

July 1, 2026

Status Verified

June 1, 2026

Enrollment Period

2.3 years

First QC Date

June 25, 2026

Last Update Submit

June 25, 2026

Conditions

Whole Body ImagingProstateMRILungVascular

Keywords

MRIWhole BodyAccelerated ImagingProstate ImagingVascular

Outcome Measures

Primary Outcomes (1)

  • Image quality

    Comparison between standard and accelerated MRI sequences in terms of diagnostic accuracy, acquisition time.

    30 months

Secondary Outcomes (1)

  • Image quality - subjective

    30-36 months

Eligibility Criteria

Age18 Years+
Sexall(Gender-based eligibility)
Gender Eligibility DetailsAt least 50% male population
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Consecutive adults (≥18 years) admitted to the Advanced Imaging for Personalized Medicine Unit for screening WB-MRI, including a male subgroup undergoing prostate-focused imaging to rule out malignancy. Subjects refusing consent, with claustrophobia, or with metallic implants compromising image quality are excluded.

You may qualify if:

  • Consecutive adults (≥18 y.o.) admitted to the UO for W MRI for screening procedure.
  • Consecutive adult male patients (≥18 y.o.) admitted to the UO for WB-MRI for screening procedure and focus on prostate.

You may not qualify if:

  • refused to consent
  • claustrophobia
  • metal prosthesis potentially affecting image quality

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (6)

  • Kim BK, Kim JS, Lee HJ, Lee JK, Lee HA, Pak S. Low- Versus High-Concentration Iodine Contrast for Hepatic Multiphase CT in Chronic Liver Disease: Image Quality, Lesion Detectability, and Iodine Load Reduction with Modern MDCT-A Retrospective Non-Inferiority Study. Diagnostics (Basel). 2025 Nov 27;15(23):3026. doi: 10.3390/diagnostics15233026.

    PMID: 41374407BACKGROUND

  • Breit HC, Vosshenrich J, Hofmann V, Rusche T, Kovacs BK, Bach M, Manneck S, Harder D. Image Quality of Lumbar Spine Imaging at 0.55T Low-Field MRI is Comparable to Conventional 1.5T MRI - Initial Observations in Healthy Volunteers. Acad Radiol. 2023 Nov;30(11):2440-2446. doi: 10.1016/j.acra.2023.01.037. Epub 2023 Feb 24.

    PMID: 36841743BACKGROUND

  • Haller S, Hedderich D, Federau C, Weisstanner C, Edjlali M, Cauter SV, Zaharchuk G. The Current Status of AI-accelerated MRI Techniques in Clinical Use. Radiology. 2025 Nov;317(2):e243819. doi: 10.1148/radiol.243819.

    PMID: 41186470BACKGROUND

  • Li C, Lei S, Ding L, Xu Y, Wu X, Wang H, Zhang Z, Gao T, Zhang Y, Li L. Global burden and trends of lung cancer incidence and mortality. Chin Med J (Engl). 2023 Jul 5;136(13):1583-1590. doi: 10.1097/CM9.0000000000002529.

    PMID: 37027426BACKGROUND

  • Rata M, Blackledge M, Scurr E, Winfield J, Koh DM, Dragan A, Candito A, King A, Rennie W, Gaba S, Suresh P, Malcolm P, Davis A, Nilak A, Shah A, Gandhi S, Albrizio M, Drury A, Roberts S, Jenner M, Brown S, Kaiser M, Messiou C. Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma. Insights Imaging. 2022 Jul 28;13(1):123. doi: 10.1186/s13244-022-01253-0.

    PMID: 35900614BACKGROUND

  • Petralia G, Koh DM, Attariwala R, Busch JJ, Eeles R, Karow D, Lo GG, Messiou C, Sala E, Vargas HA, Zugni F, Padhani AR. Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening. Radiology. 2021 Jun;299(3):494-507. doi: 10.1148/radiol.2021201740. Epub 2021 Apr 27.

    PMID: 33904776BACKGROUND

Central Study Contacts

Antonio Esposito, Medicine and Surgery

CONTACT

+390226436185esposito.antonio@unisr.it

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 25, 2026

First Posted

July 1, 2026

Study Start

July 1, 2026

Primary Completion (Estimated)

November 1, 2028

Study Completion (Estimated)

May 1, 2029

Last Updated

July 1, 2026

Record last verified: 2026-06